In the present study, the influence of previous immune checkpoint inhibitor (ICI) therapy with ramucirumab (RAM) + docetaxel (DTX) therapy on the occurrence of severe neutropenia in patients with non-small cell lung cancer (NSCLC) was evaluated, taking into account the influences of cytotoxic chemotherapy used in pretreatment. The study participants included patients who received a combination therapy of RAM and DTX as cancer chemotherapy for NSCLC. The influences of previous ICI treatment and pretreatment with cytotoxic anticancer agents on the development of grade ≥ 3 neutropenia were analysed. A total of 89 patients, including 50 with and 39 without a history of ICI treatment, were analysed. Kaplan-Meier curves showed a significant difference in the influence of previous ICI treatment on the development of grade ≥ 3 neutropenia (p= 0.006). Moreover, Cox regression analysis identified a history of ICI treatment and prophylactic administration of G-CSF as factors associated with the development of grade ≥ 3 neutropenia (p= 0.018 andp< 0.001, respectively). This study found that previous treatment with ICIs reduced the incidence of grade ≥ 3 neutropenia after RAM + DTX therapy in patients with NSCLC, regardless of the influences of pretreatment with cytotoxic anticancer agents.
本研究评估了既往免疫检查点抑制剂（ICI）治疗对非小细胞肺癌（NSCLC）患者接受雷莫西尤单抗（RAM）联合多西他赛（DTX）治疗后发生严重中性粒细胞减少症的影响，并考虑了前期使用细胞毒性化疗的影响。研究对象为接受RAM联合DTX作为NSCLC化疗方案的患者。分析了既往ICI治疗及前期细胞毒性抗癌药物对≥3级中性粒细胞减少症发生的影响。共纳入89例患者，其中50例有ICI治疗史，39例无ICI治疗史。Kaplan-Meier曲线显示既往ICI治疗对≥3级中性粒细胞减少症的发生存在显著影响（p=0.006）。此外，Cox回归分析确定ICI治疗史和预防性使用G-CSF是与≥3级中性粒细胞减少症发生相关的因素（分别为p=0.018和p<0.001）。本研究发现，无论前期细胞毒性抗癌药物的影响如何，既往ICI治疗降低了NSCLC患者接受RAM+DTX治疗后≥3级中性粒细胞减少症的发生率。
肿瘤(癌症)患者之家